Benzhydrazone [BH;indene-1,3(2H)-dionebis(amidinohydrazone)] significantly inhibits glycosylation of proteins, but only in cells infected with herpes simplex virus. We report on a herpes simplex virus type 1 (HSV-1) mutant resistant to BH. A syncytium-inducing mutant designated HSV-1(13)S11 was found to be biochemically resistant to BH in that [14C]glucosamine incorporation was not inhibited in infected HEp-2 cells exposed to the drug. Intertypic recombinants were obtained which showed that BH resistance is encoded in the DNA of the mutant virus and may be transferred into the genome of BH-sensitive HSV. In the recombinants the biochemical resistance marker segregated from the syncytial marker, suggesting that the two markers probably map in different loci. The BH-resistant mutant did not complement wild-type BH-sensitive HSV-1 and -2. Furthermore, resistance was apparent in HEp-2 but not in Vero cells. The paper discusses the hypothesis that inhibition of glycosylation of HSV proteins is the consequence of modification or selective transport of BH involving a HSV gene product. ing intertypic recombinants, we observed that BH resistance is encoded in HSV-1(13)S11 DNA and may be transferred from the genome of the resistant mutant into the genome of HSV-2(G).
rivative [lH-benz[flindene-1,3(2H)-dionebis(amidinohydrazone)], designated benzhydrazone (BH), inhibits glycosylation of the major herpes simplex virus type 1 (HSV-1) glycoproteins (1, 2) . BH appears to be a selective inhibitor of herpesvirus glycosylation in that it does not affect HSV-1 protein synthesis or the glycosylation of uninfected cells, Sindbis virus, or paramyxovirus proteins (2) . Studies on glycopeptide size-distribution and endo-,B-N-acetylglucosaminidase H sensitivity of HSV glycoproteins formed in the presence of BH indicated that the compound prevents high-mannose oligosaccharide addition to proteins (3) . BH causes, therefore, an early block in the asparagine-linked N-glycosylation process similar to that induced by tunicamycin. Along with glycosylation, BH inhibits herpesvirus-induced cell fusion and reduces the yield of infectious virus (2) .
The observation that glycosylation of all HSV glycoproteins may be selectively inhibited by BH suggested that HSV DNA encodes a function that activates BH, or permits its penetration into the infected cells, or participates in glycosylation of viral proteins. If this were the case, it would be expected that mutants resistant to BH might occur and should be selectable. The objective of these studies was to test this hypothesis. Among several mutants tested, the syncytiuminducing (Syn-) mutant HSV-1(13)S11 appeared to be BHresistant (BHR) in that the compound did not inhibit incorporation of [14C] glucosamine into infected cells. By constructing intertypic recombinants, we observed that BH resistance is encoded in HSV-1(13)S11 DNA and may be transferred from the genome of the resistant mutant into the genome of HSV-2(G).
MATERIALS AND METHODS
Materials. BH was synthesized as previously described (1).
Viruses and Cells. The BH-resistant (BHR) mutant HSV-1(13)S11 is a Syn-mutant selected from HEp-2 cell cultures infected with stocks obtained after 5-bromodeoxyuridine mutagenesis of the non-syncytium-inducing (Syn') HSV-1(13) (4) ; isolation and selection were as described for HSV-1(13)B4 (5). HSV-1(HFEM)H6 was described (6 Glycoprotein and Protein Synthesis. Labeling media for glycoproteins and proteins consisted, respectively, of minimal essential medium containing '/2 the usual concentration of glucose and [14C]glucosamine (2-3 ,uCi/ml, 50 mCi/mmol, the Radiochemical Center, Amersham; 1 Ci = 37 GBq) or minimal essential medium containing V/1o the usual concentration of methionine and [35S]methionine (25 ,uCi/ml, >400 Ci/mmol, New England Nuclear). Glycoproteins were labeled between 14 and 20 hr after infection. a polypeptides were detected by exposing cells to cycloheximide (5 ,ug/ml) from 1 hr before virus adsorption to 5 hr after infection and by labeling for 20 min after cycloheximide removal. , and y polypeptides were labeled from 5 to 7 and from 15 to 18 hr after infection, respectively. Protein nomenclature was according to Morse et al. (7) . Details for harvesting cells and measuring trichloroacetic acid-precipitable radioactive material were described (2) . NaDodSO4 electrophoresis of glycoproteins and proteins was on 8.5% polyacrylamide gels crosslinked with NN'-diallyl tartardiamide.
Intertypic Marker Transfer. Intertypic marker transfer was done essentially as described (8, 9 Proc. Natl. Acad Sci. USA 81 (1984) 2441 plaques were selected from the viral progeny of transfected cells and were plaque purified three more times before preparing the virus stocks. Purification and digestion of DNAs cut with restriction endonucleases were as described (9) . RESULTS Selection of a BHR Mutant: HSV-1(13)Sll. We analyzed several Syn-HSV-1 mutants to identify a BHR mutant. We took advantage of the observation that BH, as an inhibitor of HSV glycosylation, prevents cell fusion induced by Synmutants of HSV. Therefore, as a criterion in search for BHR mutants, we looked for Syn-mutants retaining the Synphenotype when infected cells were exposed to the compound. Among the Syn-mutants tested, one designated HSV-1(13)S11, isolated from mutagenized stock of HSV-1(13) wild-type (Syn+) virus (4, 5) , caused cell fusion in the presence of the drug. Appearance of polykaryocytes was only retarded by BH by 1-2 hr. Subsequent studies showed that the drug did not significantly inhibit [14C]glucosamine incorporation in HSV-1(13)Sll-infected HEp-2 cells labeled from 12-14 to 20 hr after infection-i.e., after onset of fusion in both untreated and BH-treated cultures ( Table 1 ). The parental Syn+ HSV-1(13) was sensitive to inhibition by BH, though to a lower extent than HSV-1(MP) (2), which was included as a BH-sensitive (BHs) control and for comparison (Table 1) . It is of interest, however, that HSV-1(13)S11 expressed the resistant phenotype in HEp-2 cells and not in Vero cells (data not shown).
Analyses of the Glycoproteins and of the Polypeptides Specified by HSV-1(13)Sll and Its Parent HSV-1 (13) . Fig. 1 shows that the electrophoretic pattern of HSV-1(13)Sll glycoproteins synthesized in the absence of BH did not differ from that of glycoproteins synthesized in the presence of the drug. Unlike the parental HSV-1(13), glycoprotein C does not accumulate in HSV-1(13)S11-infected cells, as is frequently the case in Syn-mutants, which fuse HEp-2 cells (10). with parental HSV-1 (13) and labeled between 5 and 7 or 15 and 18 hr after infection. The significant conclusion is that the BH does not alter the pattern of protein synthesis either in the HSV-1(13) parent strain or in the HSV-1(13)Sll mutant, in accordance with previous data (2). However, significant differences were observed between the polypeptides synthesized by the parental and the mutant strains. The main ones concerned infected cell polypeptides 15, 23, 32, and 35, which were present in detectable amounts only in HSV-1(13)-infected cells. These proteins belong to the subset of y proteins made late in infection and dependent on viral DNA synthesis for their expression (11) . The electrophoretic profiles of a polypeptides specified by the parental and the mutant strain did not differ (data not shown). No differences were observed in the patterns of f proteins. The subset of early y proteins (e.g., ICP 5) dependent on DNA synthesis for normal yields but not for the initiation of their synthesis was only slightly reduced. Whether absence of some polypeptides in HSV-1(13)S11-infected cells is relevant to the expression of the BHR phenotype remains to be determined. HindIII-digested HSV-1(13)S11 DNA and intact HSV-2(G) DNA. The progeny of individual Syn-plaques were harvested, purified, and analyzed with restriction endonucleases. The electrophoretic pattern of recombinants DNA could not be differentiated from that of HSV-2(G) when cut with Kpn I (Fig. 3) 
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DISCUSSION
In this paper, we report on the properties of a mutant resistant to BH. Relevant to the conclusions of this paper are the following: (i) BH reduces the asparagine-linked N-glycosylation of HSV-1 and HSV-2 glycoproteins in both HEp-2 and Vero cells. The effect is HSV specific in the sense that the drug does not affect the glycosylation of the proteins of other viruses (Sindbis virus and paramyxoviruses). In HSV-1-infected cells, the pattern of protein synthesis in treated cells (2) cannot be differentiated from that of untreated cells.
(ii) If the effect of BH were HSV specific, it should be possible to obtain mutants resistant to the drug. We took advantage of the observation that BH inhibits the fusion of infected cells into polykaryocytes by Syn-mutants to screen for mutants resistant to BH. The Syn-mutant HSV-1(13)S11 turned out to be resistant to the drug. Further (14) . The resistance to BH expressed by the HSV-1(13)S11 mutant is recessive in cells doubly infected with mutant and wild type. The data suggest, therefore, that the mutation in HSV-1(13)S11 resulted in a loss of a function. Consistent with this conclusion is the observation that the synthesis of several late y proteins (y2 proteins), which are stringently dependent on the onset of repli- 
